低分子肝素治疗易栓症复发性流产的疗效分析

Therapeutic Effect of Low Molecular Weight Heparin on Recurrent Miscarriage with Thrombophilia

目的分析低分子肝素治疗易栓症复发性流产的疗效。方法选择2017年3月—2019年3月到该院就诊的182例妊娠并有易栓症风险患者为研究对象,随机分成对照组和研究组,每组91例。对照组患者常规给予地屈孕酮、叶酸和维生素E。而研究组则在对照组治疗基础上给予低分子肝素治疗。观察两组患者抗凝血酶-III、蛋白C、蛋白S、D二聚体等易栓症标志物血清生化指标和不良妊娠结局情况,并进行比较。结果对比两组患者血清生化指标,结果显示研究组患者抗凝血酶-III(104.13±11.71)%、蛋白C(77.05±5.83)%和蛋白S(83.51±10.25)%的水平趋于正常,明显高于对照组,差异有统计学意义(t=6.371、17.650、8.799,P<0.05);研究组患者血清D-二聚体浓度明显低于对照组趋于正常,差异有统计学意义(P<0.05)。研究组患者胎儿生长受限、再次流产、新生儿窒息、低体重儿及胎盘早剥等不良妊娠结局的发生率明显低于对照组,差异有统计学意义(P<0.05)。结论低分子肝素治疗易栓症复发性流产疗效显著,可降低妊娠期易栓症孕妇不良妊娠结局的发生率。

Objective To analyze the efficacy of low molecular weight heparin in the treatment of recurrent miscarriage with thrombophilia. Methods A total of 182 pregnant patients with risk of thrombosis who visited the hospital from March 2017 to March 2019 were selected as the research subjects, and were randomly divided into a control group and a research group, with 91 cases in each group. Patients in the control group were given dydrogesterone, folic acid and vitamin E routinely. The research group was given low-molecular-weight heparin treatment based on the control group.Observe the serum biochemical indicators and adverse pregnancy outcomes of antithrombin-III, protein C, protein S, D dimer and other thrombosis markers in the two groups. Results Comparing the serum biochemical indexes of the two groups of patients, the results showed that the levels of antithrombin-III(104.13 ± 11.71)%, protein C(77.05±5.83)%and protein S(83.51±10.25)% in the study group tended to be normal, significantly higher than the control group, the difference was statistically significant(t=6.371, 17.650, 8.799, P<0.05);the serum D-dimer concentration in the study group was significantly lower than that of the control group, the difference was statistically significant(P<0.05). The incidence of adverse pregnancy outcomes in the study group, including fetal growth restriction, re-abortion, neonatal asphyxia, low-birthweight infants, and placental abruption, was significantly lower than that in the control group, the difference was statistically significant(P<0.05). Conclusion Low-molecular-weight heparin is effective in the treatment of recurrent miscarriage with thrombophilia, which can reduce the incidence of adverse pregnancy outcomes in pregnant women with thrombophilia during pregnancy.